Kingsman S - Search Results

1

Characterization of physiologically regulated vectors for the treatment of ischemic disease.

Boast K, Binley K, Iqball S, Price T, Spearman H, Kingsman S, Kingsman A, Naylor S. Boast K, et al. Among authors: kingsman s, kingsman a. Hum Gene Ther. 1999 Sep 1;10(13):2197-208. doi: 10.1089/10430349950017185. Hum Gene Ther. 1999. PMID: 10498251

2

Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy.

Binley K, Askham Z, Iqball S, Spearman H, Martin L, de Alwis M, Thrasher AJ, Ali RR, Maxwell PH, Kingsman S, Naylor S. Binley K, et al. Among authors: kingsman s. Blood. 2002 Oct 1;100(7):2406-13. doi: 10.1182/blood-2002-02-0605. Blood. 2002. PMID: 12239150 Free article.

3

An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer.

Binley K, Iqball S, Kingsman A, Kingsman S, Naylor S. Binley K, et al. Among authors: kingsman s, kingsman a. Gene Ther. 1999 Oct;6(10):1721-7. doi: 10.1038/sj.gt.3301001. Gene Ther. 1999. PMID: 10516721

4

The macrophage - a novel system to deliver gene therapy to pathological hypoxia.

Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S, Naylor S. Griffiths L, et al. Among authors: kingsman s. Gene Ther. 2000 Feb;7(3):255-62. doi: 10.1038/sj.gt.3301058. Gene Ther. 2000. PMID: 10694803

5

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer.

Kan O, Griffiths L, Baban D, Iqball S, Uden M, Spearman H, Slingsby J, Price T, Esapa M, Kingsman S, Kingsman A, Slade A, Naylor S. Kan O, et al. Among authors: kingsman s, kingsman a. Cancer Gene Ther. 2001 Jul;8(7):473-82. doi: 10.1038/sj.cgt.7700329. Cancer Gene Ther. 2001. PMID: 11498768

6

Hypoxia-mediated tumour targeting.

Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S. Binley K, et al. Among authors: kingsman s. Gene Ther. 2003 Apr;10(7):540-9. doi: 10.1038/sj.gt.3301944. Gene Ther. 2003. PMID: 12646859

7

Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency.

Slingsby JH, Baban D, Sutton J, Esapa M, Price T, Kingsman SM, Kingsman AJ, Slade A. Slingsby JH, et al. Among authors: kingsman sm, kingsman aj. Hum Gene Ther. 2000 Jul 1;11(10):1439-51. doi: 10.1089/10430340050057512. Hum Gene Ther. 2000. PMID: 10910141

8

Cytochrome P450-based cancer gene therapy: current status.

Kan O, Kingsman S, Naylor S. Kan O, et al. Among authors: kingsman s. Expert Opin Biol Ther. 2002 Dec;2(8):857-68. doi: 10.1517/14712598.2.8.857. Expert Opin Biol Ther. 2002. PMID: 12517265 Review.

9

Effects of stoichiometry of retroviral components on virus production.

Yap MW, Kingsman SM, Kingsman AJ. Yap MW, et al. J Gen Virol. 2000 Sep;81(Pt 9):2195-2202. doi: 10.1099/0022-1317-81-9-2195. J Gen Virol. 2000. PMID: 10950977

10

Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications.

Farley DC, Iqball S, Smith JC, Miskin JE, Kingsman SM, Mitrophanous KA. Farley DC, et al. Among authors: kingsman sm. J Gene Med. 2007 May;9(5):345-56. doi: 10.1002/jgm.1022. J Gene Med. 2007. PMID: 17366519

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters